Compare Medtronic PLC (MDT) vs Progressive Corp (PGR) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

PGR trades at $211.22, up 1.57% over 24 hours, with a bearish technical signal but neutral oscillators. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin expanding to 12.9%. Recent Q2 2026 earnings matched expectations at $4.64 EPS. Analyst consensus price target is $234.56 with 37% buy ratings, though technical resistance looms near $212.

Outlook remains cautiously optimistic given Progressive's earnings consistency and valuation at 10.43 P/E, but risks include competitive pressures and potential earnings volatility. The stock offers value with dividend yield support, though investors should monitor premium growth sustainability amid economic uncertainty.